Pregabalin Zentiva

Country: European Union

Language: Slovak

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalín

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptiká,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

oprávnený

Authorization date:

2015-07-17

Patient Information leaflet

                                1
PRÍLOHA I
SÚHRN CHARAKTERISTICKÝCH VLASTNOSTÍ LIEKU
2
1.
NÁZOV LIEKU
Pregabalin Zentiva 25 mg tvrdé kapsuly
Pregabalin Zentiva 50 mg tvrdé kapsuly
Pregabalin Zentiva 75 mg tvrdé kapsuly
Pregabalin Zentiva 100 mg tvrdé kapsuly
Pregabalin Zentiva 150 mg tvrdé kapsuly
Pregabalin Zentiva 200 mg tvrdé kapsuly
Pregabalin Zentiva 225 mg tvrdé kapsuly
Pregabalin Zentiva 300 mg tvrdé kapsuly
2.
KVALITATÍVNE A KVANTITATÍVNE ZLOŽENIE
Pregabalin Zentiva 25 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 25 mg pregabalínu.
Pomocné látky
so známym účinkom
Každá tvrdá kapsula obsahuje tiež 47,57 mg monohydrátu laktózy.
Pregabalin Zentiva 50 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 50 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 5 mg monohydrátu laktózy.
Pregabalin Zentiva 75 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 75 mg pregabalínu.
Pomocné
látky so známym úč
inkom
Každá tvrdá kapsula obsahuje tiež 7,5 mg monohydrátu laktózy.
Pregabalin Zentiva 100 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 100 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 10 mg monohydrátu laktózy.
Pregabalin Zentiva 150 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 150 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 15 mg monohydrátu laktózy.
Pregabalin Zentiva 200 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 200 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 20 mg monohydrátu laktózy.
Pregabalin Zentiva 225 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 225 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 22,5 mg monohydrátu laktózy.
Pregabalin Zentiva 300 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 300 mg pregabalínu.
3
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 30 mg monohydrátu laktózy.
Úplný zoznam po
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRÍLOHA I
SÚHRN CHARAKTERISTICKÝCH VLASTNOSTÍ LIEKU
2
1.
NÁZOV LIEKU
Pregabalin Zentiva 25 mg tvrdé kapsuly
Pregabalin Zentiva 50 mg tvrdé kapsuly
Pregabalin Zentiva 75 mg tvrdé kapsuly
Pregabalin Zentiva 100 mg tvrdé kapsuly
Pregabalin Zentiva 150 mg tvrdé kapsuly
Pregabalin Zentiva 200 mg tvrdé kapsuly
Pregabalin Zentiva 225 mg tvrdé kapsuly
Pregabalin Zentiva 300 mg tvrdé kapsuly
2.
KVALITATÍVNE A KVANTITATÍVNE ZLOŽENIE
Pregabalin Zentiva 25 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 25 mg pregabalínu.
Pomocné látky
so známym účinkom
Každá tvrdá kapsula obsahuje tiež 47,57 mg monohydrátu laktózy.
Pregabalin Zentiva 50 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 50 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 5 mg monohydrátu laktózy.
Pregabalin Zentiva 75 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 75 mg pregabalínu.
Pomocné
látky so známym úč
inkom
Každá tvrdá kapsula obsahuje tiež 7,5 mg monohydrátu laktózy.
Pregabalin Zentiva 100 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 100 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 10 mg monohydrátu laktózy.
Pregabalin Zentiva 150 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 150 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 15 mg monohydrátu laktózy.
Pregabalin Zentiva 200 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 200 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 20 mg monohydrátu laktózy.
Pregabalin Zentiva 225 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 225 mg pregabalínu.
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 22,5 mg monohydrátu laktózy.
Pregabalin Zentiva 300 mg tvrdé kapsuly
Každá tvrdá kapsula obsahuje 300 mg pregabalínu.
3
Pomocné
látky so známym účinkom
Každá tvrdá kapsula obsahuje tiež 30 mg monohydrátu laktózy.
Úplný zoznam po
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 27-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 19-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 27-07-2015

Search alerts related to this product